Validated using a knockout cell line
Recombinant
RabMAb

Anti-SLC25A13 antibody [EPR9969(B)] (ab167166)

Overview

  • Product name
    Anti-SLC25A13 antibody [EPR9969(B)]
    See all SLC25A13 primary antibodies
  • Description
    Rabbit monoclonal [EPR9969(B)] to SLC25A13
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human SLC25A13 (C terminal). The exact sequence is proprietary.

  • Positive control
    • Human fetal liver, HepG2 and SH-SY5Y cell lysates.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab167166 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 70 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.
  • Target

    • Function
      Catalyzes the calcium-dependent exchange of cytoplasmic glutamate with mitochondrial aspartate across the mitochondrial inner membrane. May have a function in the urea cycle.
    • Tissue specificity
      High levels in liver and low levels in kidney, pancreas, placenta, heart and brain.
    • Involvement in disease
      Defects in SLC25A13 are the cause of citrullinemia type 2 (CTLN2) [MIM:603471]. Citrullinemia belongs to the urea cycle disorders. It is an autosomal recessive disease characterized primarily by elevated serum and urine citrulline levels. Ammonia intoxication is another manifestation. CTLN2 is characterized by neuropsychiatric symptoms including abnormal behaviors, loss of memory, seizures and coma. Death can result from brain edema. Onset is sudden and usually between the ages of 20 and 50 years.
      Defects in SLC25A13 are the cause of neonatal intrahepatic cholestasis due to citrin deficiency (NICCD) [MIM:605814]. NICCD is a form of citrullinemia type 2 with neonatal onset. NICCD is characterized by suppression of the bile flow, hepatic fibrosis, low birth weight, growth retardation, hypoproteinemia, variable liver dysfunction. NICCD is generally not severe and symptoms disappear by one year of age with an appropriate diet. Years or even decades later, however, some individuals develop the characteristic features of citrullinemia type 2 with neuropsychiatric symptoms.
    • Sequence similarities
      Belongs to the mitochondrial carrier family.
      Contains 4 EF-hand domains.
      Contains 3 Solcar repeats.
    • Cellular localization
      Mitochondrion inner membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • AI785475 antibody
      • ARALAR2 antibody
      • Calcium binding mitochondrial carrier protein Aralar2 antibody
      • Calcium-binding mitochondrial carrier protein Aralar2 antibody
      • Citrin antibody
      • CMC2_HUMAN antibody
      • CTLN2 antibody
      • Ctrn antibody
      • Mitochondrial aspartate glutamate carrier 2 antibody
      • RGD1565889 antibody
      • Slc25a13 antibody
      • Solute carrier family 25 (citrin) member 13 antibody
      • Solute carrier family 25 member 13 (citrin) antibody
      • Solute carrier family 25 member 13 antibody
      see all

    Images

    • Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: SLC25A13 knockout HAP1 cell lysate (20 µg)
      Lane 3: SH-5YSY cell lysate (20 µg)

      Lanes 1 - 3: Merged signal (red and green). Green - ab167166 observed at 70 kDa. Red - loading control, ab8245, observed at 37 kDa.
      ab167166 was shown to recognize SLC25A13 when SLC25A13 knockout samples were used, along with additional cross-reactive bands. Wild-type and SLC25A13 knockout samples were subjected to SDS-PAGE. ab167166 and ab8245 (loading control to GAPDH) were diluted at 1/500 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

    • All lanes : Anti-SLC25A13 antibody [EPR9969(B)] (ab167166) at 1/1000 dilution

      Lane 1 : Human fetal liver lysates
      Lane 2 : HepG2 cell lysates
      Lane 3 : SH-SY5Y cell lysates

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size: 70 kDa

    References

    ab167166 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab167166.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up